S3-E63.3 – Year-End Interview with Ian Rowe
In this final segment, Ian Rowe joins Jörn and Roger to share his takeaways.
December 31, 2022
In this final segment, Ian Rowe joins Jörn and Roger to share his takeaways.
In the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022.
In the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022. In this exclusive segment, Naim Alkhouri joins Louise and Roger to discuss drugs, NITs, digital diagnostics and the importance of preventing pediatric and adolescent NAFLD.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the final installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Naim Alkhouri, Stephen Harrison and Ian Rowe to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Jeff Lazarus to discuss a “drugs-plus” approach to liver disease, interprofessional collaboration, guidelines and much more.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Ken Cusi to discuss two major trends: publication and adoption of guidelines and clinical care pathways that increase requirements from screening in primary care and endocrinology settings, and promising Phase 3 trials that suggest new NASH drugs are on a shorter-term horizon.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the second installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Mazen Noureddin, Ken Cusi and Jeff Lazarus to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This final conversation discusses what the announcement could mean for combination therapy and adjacent drug development stories. Each panelist provides closing thoughts to the session, offering diverse perspectives and an array of key takeaways.
This week, Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the basic science of this study and the impact it will have on future use of NITs.
A highly anticipated NASH-TAG 2023 takes place in Park City, Utah on January 5-7, 2023. In this episode, Stephen Harrison previews the conference agenda and shares his perspective on Madrigal’s announcement of positive topline results from the MAESTRO-NASH trial of resmetirom.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the implications of the Madrigal program, offering compelling commentary from a group of eight panelists with varying perspectives and takeaways.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story. This conversation offers varying first impressions and perspectives from the group of eight.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts an exclusive conversation with Founder and CEO of the Global Liver Institute, Donna Cryer.
Yesterday, Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. In this installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Donna Cryer to discuss GLI’s preparations for a promising 2023, promoting patient perspectives, liver health awareness and much more.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. In this feature, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Hannes Hagström to discuss his studies in 2022 and beyond. Hannes provides an insight-laden tour of the myriad of research directions derived from a population-based cohort of liver disease patients in Sweden.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this first installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Scott Friedman to discuss the year in review, advancements in liver science, and more.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the first installation of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Scott Friedman, Hannes Hagström and Donna Cryer to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
This conversation From the Vault revisits the moment Jörn Schattenberg joined the permanent Surfing crew. He sits with Louise Campbell and Roger Green to share his background and focus and to discuss where SurfingNASH.com will take NASH Tsunami in its third full year.
This conversation From the Vault revisits the moment Jörn Schattenberg joined the permanent Surfing crew. He sits with Louise Campbell and Roger Green to share his background and focus and to discuss where SurfingNASH.com will take NASH Tsunami in its third full year.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022. In this final conversation, Jörn Schattenberg, Louise Campbell and Roger Green discuss NAIL-NIT retrospective analysis data and the role of consortia in reshaping the focus of NITs.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022. In this conversation, Jörn Schattenberg, Louise Campbell and Roger Green discuss the expanding benefits of FibroScan through newer iterations of the product and integrating digital tools.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022. This conversation features the impressions of Jörn Schattenberg, Louise Campbell and Roger Green on returning to in-person meetings and the expectation that NICE is primed to approve FibroScan for primary care under specific circumstances.
Surfing the NASH Tsunami hosts its third NAFLD Year-in-Review – our look at key highlights of 2022 featuring the impressions of Jörn Schattenberg, Louise Campbell and Roger Green. This discussion looks at the return to in-person conferences and events, NICE on FibroScan, progress in NITs, potential pathway developments and much more.
In this episode From the Vault, Antaros Medical’s Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his 2021 Paris NASH talk. This conversation revolves around the implications of Lars’s comment that we should track and analyze functioning hepatocyte cells as an excellent marker for liver function.
In discussing the Liver Forum, Executive Director Veronica Miller joins guest Manal Abdelmalek, co-host Jörn Schattenberg and Roger Green to investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. In this final conversation, Veronica, Manal and Jörn each provide their unique perspectives on critical success factors for placebo cohorts.
Executive Director Veronica Miller joins guest Manal Abdelmalek and co-host Jörn Schattenberg (both Steering Committee members) to discuss ongoing activities of the Liver Forum. This conversation explores a priori placebo response rates and challenges in managing samples through trials.
Executive Director Veronica Miller joins guest Manal Abdelmalek and co-host Jörn Schattenberg (both Steering Committee members) to introduce the origins of the Liver Forum. This conversation goes on to explore an ongoing project aimed to develop research tools and metrics that can capture the richness available in a plethora of data emerging from NASH studies.
In this conversation, Executive Director Veronica Miller introduces her path to the Liver Forum. She details her career history in HIV research and the establishment of the HIV Forum before working on HCV and eventually NAFLD.
In this episode discussing the Liver Forum, Jörn Schattenberg, Manal Abdelmalek, Veronica Miller and Roger Green investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. Jörn, Manal and Veronica each provide their unique introductions to the steering committee and elaborate on the Forum’s efforts toward moving the field forward.
This episode From the Vault focuses on the importance of NASH cirrhosis clinical trials. The conversation summarizes the status of four ongoing trials and addresses issues of disease naming and the value of incorporating MRE into trial designs.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this final conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to discuss key takeaways for physicians working with nutrition and lifestyle modification in an integrative approach for NASH resolution.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to discuss integrated solutions to provide more information and better support to patients.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to explore the psychology of decision-making around diet and professional support.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. This conversation continues in the theme of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications. Shira describes her own approach, termed weight-inclusive, which focuses on holistic coaching measures which extend to all facets of a happy and healthy lifestyle.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are panelists Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. This conversation introduces the topic of weight reduction for NASH resolution, and strategies for long-term adherence to lifestyle modifications.
Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green in this rich, applicable and fascinating discussion.
This conversation From the Vault observes highlights from the last section of the NASH-Day Wrap-up Panel at Global Liver Institute for #NASHDay 2022. GLI NASH Programs Director Jeff McIntyre asks the panelists what #StopNASHNow means to them. Jörn Schattenberg, Louise Campbell and Roger Green provide the answers.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This final conversation discusses the diversity of populations with NASH before closing with the group’s predictions into a new year in the field of Fatty Liver disease.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation explores emerging roles for the ELF test and advances in the use of PPARs.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation focuses around the efficacy of NITs for identifying fatty liver disease and progression in primary care and diabetes clinic settings.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation addresses several topics surrounding the importance of educating physicians on NAFLD prevalence in different systems around the globe, and key points around standardizing AST.
A panel of seven attendees (Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green) convene to recap the just-concluded 2022 AASLD Liver Meeting. This conversation focuses on an ongoing initiative of the Fatty Liver Foundation called the Annual Survey of Patient Perspectives.
Jörn Schattenberg, William Alazawi, Naim Alkhouri, Laurent Castera, Kenneth Cusi, Wayne Eskridge and Roger Green convene to recap the just-concluded 2022 AASLD Liver Meeting. The panelists touch on a range of topics from a particularly momentous event which saw many promising papers presaging an exciting upcoming year for the field of Fatty Liver.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. In an exclusive interview, Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk in depth about the company and key elements of its clinical development strategy for its pan-PPAR, lanifibranor.
Surfing the NASH Tsunami hosted two recording sessions throughout the Liver Meeting to discuss key takeaways. This conversation is a composite featuring impressions from both sessions. In the first session, panelists review the emerging role of mitochondrial uncouplers in the field of NASH. The following session offers insight from a reanalysis of results from Intercept’s Phase 3 REGENERATE Study of Obeticholic Acid.
On the final morning of the 2022 AASLD Liver Meeting, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discussed their key takeaways and impressions. Stephen leads this conversation to highlight his presentation of results from Akero Therapeutics’ Phase 2b HARMONY Study.
The 73rd Annual AASLD Liver Meeting proved to be a lively and momentous event held in Washington DC. On the final morning, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe and Jeff McIntyre joined Roger Green to discuss key takeaways and impressions. In this conversation, the panelists focus on utilizing best practices in diagnostics.
In this conversation, Jeff McIntyre leads with his impressions on the pan-society presentation of NAFLD nomenclature consensus process. He begins with an objective account of
Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Liver Meeting on site in Washington DC. In this conversation, the group discusses serum metabolomics, gene therapy and the waning future of biopsy.
Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Liver Meeting on site in Washington DC. In this conversation, the group dives into the gut microbiome while discussing the complex nature of NAFLD.
Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe, Jeff McIntyre and Roger Green discuss key takeaways on the final morning of the 73rd Annual AASLD Liver Meeting. The group embarks on a far reaching conversation to cover at length topics including tests, drugs and nomenclature amongst many more impressions. Following the review, Roger and Stephen interview Michael Cooreman from Inventiva to discuss the focus of the clinical-stage biopharmaceutical company and its relevance to the field of Fatty Liver.
Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Liver Meeting on site in Washington DC.
Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation From the Vault focuses on how to make NITs the “gold standard” of drug development instead of biopsy.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in finalizing a second preview of key presentations and posters of interest.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. This conversation explores abstracts on the NAFLD-Metabolic link and continues discussion around optimal screening tools.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this conversation, the panelists explore the potential of remote wellness tools.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Ian shifts discussion toward the efficacy of various NITs and their predictive outcomes.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green in a second preview of key presentations and posters of interest. In this session, Mazen leads discussion on the way forward in diagnosing fibrotic NASH in patients with Type 2 Diabetes.
In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th, 2022 in Washington DC. In this episode From the Vault, Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to promptly recap a just-concluded 2021 AASLD Annual Liver Meeting. Discussion centers around the many areas of advance and novelty in the program, with particular attention to non-invasive testing, genomics and the increased visibility of patients and their needs.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation discusses the NAFLD-Cancer link and the importance of raising Fatty Liver awareness.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation explores patient advocate coverage of challenges facing liver health equity.
The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest. This conversation focuses on fibrosis progression rates for diabetic vs. non-diabetic patients.
